Results 201 to 210 of about 3,697,166 (278)

Sitagliptin, Metformin and Glimepiride Fixed-Dose Combination Compared to Co-Administration of Metformin and High-Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double-Blind, Double-Dummy, Phase 3 Clinical Study. [PDF]

open access: yesDiabetes Obes Metab
Sahay R   +22 more
europepmc   +1 more source

Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7367-7379, August 2026.
ABSTRACT Aims Urogenital adverse events are common with sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) and may influence treatment decisions. Variations in SGLT2i selectivity, potency and effects on renal glucose excretion could lead to differences in safety profiles. We compared the risks of urinary tract infection (UTI), genital tract infection (
Christine Ljungberg   +7 more
wiley   +1 more source

Characterization of Metabolites in Plant-Based Milk Yogurt Enriched with <i>Wolffia globosa</i> to Improve Bionutritional and Functional Properties. [PDF]

open access: yesInt J Mol Sci
Punyauppa-Path S   +7 more
europepmc   +1 more source

Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7416-7429, August 2026.
ABSTRACT Aims Empagliflozin is renoprotective in Type 2 diabetes mellitus (T2DM). Our primary aim was to assess empagliflozin's effect on glomerular filtration rate and renal vascular resistance using multiparametric MRI (MpMRI). Our secondary aim was to assess the impact of empagliflozin on additional MpMRI‐derived metrics including markers of tissue ...
Ruth P. Lim   +9 more
wiley   +1 more source

Patients' Attitudes Towards Deprescribing Differ Across Specific Cardiovascular and Diabetes Medication: A Survey Study Assessing Within-Patient Differences. [PDF]

open access: yesBasic Clin Pharmacol Toxicol
Stuijt PJC   +7 more
europepmc   +1 more source

Trends in Second‐Line Initiations and Treatment Outcomes Across Age and Frailty Groups in People With Type 2 Diabetes: UK Population‐Based Study, 2019–2024

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7471-7482, August 2026.
ABSTRACT Aims To assess contemporary UK trends in second‐line treatment initiations and outcomes across age‐and‐frailty groups in people with type 2 diabetes (T2D). Materials and Methods We studied 117 046 UK adults with T2D initiating second‐line therapy between 2019–2024 (Clinical Practice Research Datalink).
M. M. Dinsdale   +11 more
wiley   +1 more source

Characterization of Usage Patterns of Drugs Suspected to Cause Adverse Drug Reactions in Older Hospitalized Patients

open access: yesGeriatrics &Gerontology International, Volume 26, Issue 8, August 2026.
ABSTRACT Aim This study aimed to characterize the usage patterns of drugs suspected to cause adverse drug reactions (ADRs) in older hospitalized patients. Methods Medical records of older adults admitted to the Department of Geriatrics and Hypertension at Osaka University Hospital from September 2014 to August 2021 were reviewed.
Mizuki Katsuhisa   +9 more
wiley   +1 more source

Patterns and Trends of Glucose‐Lowering Therapy in Alzheimer's Disease and Related Dementias

open access: yes
Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7592-7596, August 2026.
Huilin Tang   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy